NOTICE OF TERMINATION WHEREAS, on April 1, 2002, Sanguine Corporation (the "Company" and the "Licensor") entered into an Exclusive License Agreement with Ascendiant-South America, LLC, a Nevada limited liability corporation (the "Licensee"), pursuant...Exclusive License Agreement • October 7th, 2004 • Sanguine Corp • In vitro & in vivo diagnostic substances
WHEREAS, on April 1, 2002, Sanguine Corporation (the "Company" and the "Licensor") entered into an Exclusive License Agreement with Ascendiant-South America, LLC, a Nevada limited liability corporation (the "Licensee"), pursuant to which the Licensee agreed to certain minimum levels of annual production of the Licensed Products (the "Minimum Production"); and in the event the Licensee failed to achieve the Minimum Production, to pay a royalty to the Licensor; and
Sanguine Corporation 101 East Green Street, Suite 11 Pasadena, California 91105 Attention: The Board of Directors Re: Subscription Agreement to acquire certain shares of common stock that are "restricted securities" of Sanguine Corporation, a Nevada...Subscription Agreement • October 7th, 2004 • Sanguine Corp • In vitro & in vivo diagnostic substances
Sanguine Corporation 101 East Green Street, Suite 11 Pasadena, California 91105 Attention: The Board of Directors Re: Subscription Agreement to acquire certain shares of common stock that are "restricted securities" of Sanguine Corporation, a Nevada...Subscription Agreement • October 7th, 2004 • Sanguine Corp • In vitro & in vivo diagnostic substances
Re: Subscription Agreement to acquire certain shares of common stock that are "restricted securities" of Sanguine Corporation, a Nevada corporation (the "Company"), in consideration of the cancellation of certain debt of the Company owed to the undersigned, and the contribution to capital of the Company of certain other debt of the Company to the undersigned
